Neovacs S.A RSI
Quel est le RSI de Neovacs S.A?
Le RSI de Neovacs S.A. est 47.27
Quelle est la définition de RSI?
L'indice de force relative (RSI 14) est un indicateur de dynamique qui compare l'ampleur des gains et des pertes sur une période donnée afin de mesurer la vitesse et l'évolution des mouvements de prix d'un titre.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI des entreprises dans Health Care secteur sur EURONEXT par rapport à Neovacs S.A
Que fait Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Entreprises avec rsi similaire à Neovacs S.A
- Latin American Minerals a RSI de 47.25
- SolarWinds Corp a RSI de 47.26
- BlackRock Enhanced International Dividend Trust a RSI de 47.26
- NUGL a RSI de 47.26
- BioForce Nanosciences a RSI de 47.26
- Home Bancshares Inc a RSI de 47.26
- Neovacs S.A a RSI de 47.27
- KushCo a RSI de 47.28
- ZK International Co a RSI de 47.28
- CannaGrow a RSI de 47.28
- Quantum Corp a RSI de 47.28
- Canadian Premium Sand a RSI de 47.28
- Jianpu Technology Inc a RSI de 47.28